- Home
- NCTY vs ADAG Comparison
NCTY vs ADAG Comparison
Compare NCTY & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCTY
- ADAG
- Stock Information
- Founded
- NCTY 1999
- ADAG 2011
- Country
- NCTY China
- ADAG China
- Employees
- NCTY N/A
- ADAG N/A
- Industry
- NCTY Business Services
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- NCTY Consumer Discretionary
- ADAG Health Care
- Exchange
- NCTY Nasdaq
- ADAG Nasdaq
- Market Cap
- NCTY 98.0M
- ADAG 81.9M
- IPO Year
- NCTY 2004
- ADAG 2021
- Fundamental
- Price
- NCTY $10.20
- ADAG $1.53
- Analyst Decision
- NCTY
- ADAG Strong Buy
- Analyst Count
- NCTY 0
- ADAG 1
- Target Price
- NCTY N/A
- ADAG $8.00
- AVG Volume (30 Days)
- NCTY 105.3K
- ADAG 40.8K
- Earning Date
- NCTY 01-01-0001
- ADAG 03-24-2025
- Dividend Yield
- NCTY N/A
- ADAG N/A
- EPS Growth
- NCTY N/A
- ADAG N/A
- EPS
- NCTY 9.91
- ADAG N/A
- Revenue
- NCTY $24,286,983.00
- ADAG $103,204.00
- Revenue This Year
- NCTY N/A
- ADAG $6,488.89
- Revenue Next Year
- NCTY N/A
- ADAG $57.50
- P/E Ratio
- NCTY $2.26
- ADAG N/A
- Revenue Growth
- NCTY 2.82
- ADAG N/A
- 52 Week Low
- NCTY $5.63
- ADAG $1.33
- 52 Week High
- NCTY $20.59
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- NCTY 38.89
- ADAG 42.87
- Support Level
- NCTY $9.71
- ADAG $1.47
- Resistance Level
- NCTY $12.27
- ADAG $1.92
- Average True Range (ATR)
- NCTY 1.27
- ADAG 0.18
- MACD
- NCTY -0.23
- ADAG 0.01
- Stochastic Oscillator
- NCTY 7.81
- ADAG 34.45
About NCTY The9 Limited American Depository Shares
The9 Ltd operates a cryptocurrency mining business. It provides computing power, or hash rate, to a Bitcoin mining pool and is entitled to receive a fractional share of Bitcoin award from the Bitcoin mining pool in return. The company generates its revenues from customers in Greater China and other areas.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.